(Q45954562)

18 December 2017

title

Ezetimibe in the treatment of uncontrolled hyperlipidemia in kidney transplant patients. (English)

1 reference

18 December 2017

1 reference

M L Rodríguez-Ferrero

series ordinal

1

1 reference

18 December 2017

F Anaya

series ordinal

2

1 reference

18 December 2017

language of work or name

English

0 references

publication date

1 December 2008

1 reference

18 December 2017

Transplantation Proceedings

published in

1 reference

18 December 2017

volume

40

1 reference

18 December 2017

issue

10

1 reference

18 December 2017

page(s)

3492-3495

1 reference

18 December 2017

Impact of serum lipids on long-term graft and patient survival after renal transplantation

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2008.04.018

Hyperlipidemia in solid organ transplantation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2008.04.018

Effects of immunosuppressive drugs on serum lipid levels in renal transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2008.04.018

Causes of death after renal transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2008.04.018

Efficacy and drug interactions of the new HMG-CoA reductase inhibitors cerivastatin and atorvastatin in CsA-treated renal transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2008.04.018

Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2008.04.018

Cholesterol absorption blockade with ezetimibe

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2008.04.018

Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2008.04.018

Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2008.04.018

Treatment of hypercholesterolemia with ezetimibe in the kidney transplant population

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2008.04.018

Ezetimibe in renal transplant patients with hyperlipidemia resistant to HMG-CoA reductase inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2008.04.018

A retrospective analysis of ezetimibe treatment in renal transplant recipients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2008.04.018

Ezetimibe for the treatment of uncontrolled hypercholesterolemia in patients with high-dose statin therapy after renal transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2008.04.018

MDRD equations for estimation of GFR in renal transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2008.04.018

Ezetimibe reduces low-density lipoprotein cholesterol (LDL-C) in renal transplant patients resistant to HMG-CoA reductase inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2008.04.018

Supratherapeutic response to ezetimibe administered with cyclosporine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2008.04.018

10.1016/J.TRANSPROCEED.2008.04.018

7 January 2021

Identifiers

DOI

1 reference

18 December 2017

1 reference

18 December 2017